GlassScriptPhysician profile
Sydney Jacoby
NPI 1114648649
$1,201.76
in general payments reported to CMS, 2019-2025
15 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $619 · 2024: $231 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $202.72 | 2023-2025 | |
| Genzyme Corporation | $180.02 | 2023-2025 | |
| Abbvie INC. | $167.63 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $138.77 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $113.98 | 2023-2024 | Vtama |
| Incyte Corporation | $109.33 | 2023 | Opzelura |
| Amgen INC. | $78.54 | 2023-2025 | Otezla |
| Lilly USA, LLC | $47.70 | 2023-2024 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $45.40 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $26.19 | 2024 | Dysport |
| Regeneron Healthcare Solutions, INC. | $22.88 | 2023 | Dupixent |
| Revance Therapeutics, INC. | $19.32 | 2025 | Daxxify |
| Organon LLC | $18.65 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $16.55 | 2023 | Winlevi, Absorica Ld |
| Botanix Sb INC | $14.08 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.